Cargando…
MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
BACKGROUND: PARP inhibitors have been the most promising target drugs with widely proven benefits among ovarian cancer patients. Although platinum-response, HR-related genes, or HRD genomic scar detection are acceptably used in assessment of Olaparib response, there are still evident limitations in...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995078/ https://www.ncbi.nlm.nih.gov/pubmed/32005272 http://dx.doi.org/10.1186/s13045-020-0844-0 |